NOV. 2.2005 10:38AM AVENTIS US PAT DEPT TO:US CENTRALIZED USPTO

RECEIVED CENTRAL FAX CENTER

NO. 9515 P. 1

NOV 0 2 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2008, OMB 0951-0031
U.S. Pétent and Tredemark Office; U.S. DÉPARYMENT OF COMMERCE
o a collection of information plates it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to Application Number 10/632,083 Filing Date TRANSMITTAL July 31, 2003 First Named Inventor FORM Hartmut \$TROBEL et al. Art Unit Examiner Name POWERS, Fiona (to be used for all correspondence after initial filing) Attorney Docket Number **DEAV2002/0057US NP** Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Pelilion to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request below): 1. Transmittal of IDS Fee Request for Refund Express Abandonment Request 2. Form 1449 CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name Jiang Lin Reg, No. Date 51,065 November 02, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 571-273-8300 ; Total No. of Pages Transmitted: 5 Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dale

November 02, 2005

Typed or printed name

Paul Irvine

AVENTIS US PAT DEPT

RECEIVED

NOV 0 2 2005

NO. 9515

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of STROBEL, et al.

Examiner: Powers, Fiona

Art Unit: 1626

Application No.: 10/632,083

USE AS PHARMACEUTICALS

Filed: July 31, 2003

Title: ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR

Certificate of Transmission I hereby certify that this correspondence being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit November 2, 2005

Printed Name of Person Signing Certificate Paul Irvine

Signature

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

Jiang Lin, Reg. No. 51,065

Agent for Applicant

Aventis Pharmaceuticals Inc. (a member of the sanofi-aventis group) U.S. Patent Operations Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-3582 Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0057 US NP

RECEIVED
CENTRAL FAX CENTER

E**R** NO

NO. 9515 P. 3

NOV 0 2 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of STROBEL, et al.

Application No.: 10/632,083

Filed: July 31, 2003

Title: ACYLATED, HETEROARYL-CONDENSED CYCLOALKENYLAMINES AND THEIR USE AS PHARMACEUTICALS

od. July 51, 2005

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

November 2, 2005

Examiner: Powers, Fiona

Art Unit: 1626

-/2/-

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56. 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982. 11/03/2005 MBINAS 00000008 181982

01 FC:1806

180.00 DA

10632083

NO. 9515 P. 4

\boxtimes	(b)	This Information Disclosure Statement is filed after the period set forth in 37 C.F.R.					
		1.97(b), but is believed to be filed before the mailing date of a final action under §1.113					
		or a notice of allowance under §1.311, whichever occurs first.					
		(1)	The undersigned attorney certifies that each item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				
			patent office in a counterpart foreign application not more than three months prior				
			to the filing of this statement;				
		(2)	The undersigned attorney certifies that no item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				
			patent office in a counterpart foreign application or, to the knowledge of the				
			undersigned attorney after making reasonable inquiry, was known to any				
			individual designated in §1.56(c) more than three months prior to the filing of this				
			statement; or				
	\boxtimes	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in				
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is				
			authorized.				

Respectfully submitted,

Jiang Lin, Reg. No. 51,065 Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3582
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0057 US NP

		sign (+) inside this rork Reduction Act			PTO/SB/08A (10.98) Approved for use through 10/31/89. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number.			
1	'	ute for form 1449A			Complete if Known			
ı	INE			201 201)25	Application Number	10/632,083		
				SCLOSURE	Filing Date	07-31-2003		
	STA	ATEMENT	BY	APPLICANT	First Named Inventor	STROBEL		
					Group Art Unit	1626		
ŀ		(use as many	sneets a	s necessary)	Examiner Name	POWERS, Flona		
- (Sheet	1	of	1 1	Attorney Docket Number	DEAV2002/0057 - US - NP		

U.S. PATENT DOCUMENTS							
Examiner Initials	Cile No.1	U.S. Patent I Number	Kind Codez (if known)	Name of Patentiee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passeges or Relevant Figures Appear	
		20030055093]	STROBEL	03-20-2003	- Harra Apprai	
		20040110808		STROBEL	06-10-2004		
		20040082628		STROBEL	29-04-2004		
		20040225013		STROBEL	11-11-2004		
		20050101599		ZEIHER	05-12-2005		
		6,759,412		STROBEL	07-06-2004		
		6,949,556		STROBEL	09-27-2005		
		6,617,359		STROBEL.	09-09-2003		
		6,812,253	_	STROBEL	11-02-2004	· · · · · · · · · · · · · · · · · · ·	
		20050054729		STROBEL.	03-20-2003		
			_				
$\overline{}$					 		
				•		·	
	- 1			-			

_				FORE	IGN PATENT DOCUMEN	T\$		
Examiner Inklais*	Cite No.1	Office ³	oreign Patent Do Number ⁴		Name of Palentlee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines. Where Relevant Passages or Relevant	Тө
	,		···			MINI-DD-FYFY	Floures Appear	+-
		 	· · · · · · · · · · · · · · · · · · ·	- - 				
		 						丄
		 				<u> </u>		
		 				ļ		
		-+			······································			
								T
		<u> </u>]
								T
		<u> </u>						\top

	- · · · · · · · · · · · · · · · · · · ·	•		
Examiner			Date	
Signature			Considered	
J.g. data			Considered	
SELECT INTER A	C 112 2			•

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ⁹ Enter Office that issued the document, by the two-lotter code (WIPO Standard \$T.3). ⁴ For Japanese patent documents, the indication of the year of the Telgn of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard \$T. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.